Smokeless tobacco (snus) is associated with an increased risk of type 2 diabetes: results from five pooled cohorts

Journal of Internal Medicine

Volumn 281, Issue 4, 2017, Pages 398-406

  Carlsson, S ^a   Andersson, T ^a,b   Araghi, M ^a   Galanti, R ^a,b   Lager, A ^a,b   Lundberg, M ^a,b   Nilsson, P ^c   Norberg, M ^d   Pedersen, N L ^a   Trolle Lagerros, Y ^a   Magnusson, C ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM COUNTY COUNCIL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

Author keywords

meta analysis; public health; tobacco; type 2 diabetes

Indexed keywords

ALCOHOL; INSULIN; NICOTINE; ORAL ANTIDIABETIC AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EDUCATIONAL STATUS; FOLLOW UP; HIGH SCHOOL; HUMAN; INCIDENCE; INSULIN RESISTANCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SCANDINAVIA; SELF REPORT; SNUS; DIABETES MELLITUS, TYPE 2; PROPORTIONAL HAZARDS MODEL; SMOKELESS TOBACCO; SWEDEN; UTILIZATION;

DIABETES MELLITUS, TYPE 2; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SWEDEN; TOBACCO, SMOKELESS;

EID: 85012994961     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12592     Document Type: Article

References (42)

1. https://www.folkhalsomyndigheten.se/pagefiles/23257/Folkhalsan-i-Sverige-2016-16005.pdf
2. Osterdahl BG, Jansson C, Paccou A. Decreased levels of tobacco-specific N-nitrosamines in moist snuff on the Swedish market. J Agric Food Chem 2004; 52: 5085–8.
3. Song MA, Marian C, Brasky TM, Reisinger S, Djordjevic M, Shields PG. Chemical and toxicological characteristics of conventional and low-TSNA moist snuff tobacco products. Toxicol Lett 2016; 245: 68–77.
4. Kozlowski LT, Abrams DB. Obsolete tobacco control themes can be hazardous to public health: the need for updating views on absolute product risks and harm reduction. BMC Public Health 2016; 16: 432.
5. Hansson J, Galanti MR, Hergens MP et al. Snus (Swedish smokeless tobacco) use and risk of stroke: pooled analyses of incidence and survival. J Intern Med 2014; 276: 87–95.
6. Hansson J, Galanti MR, Hergens MP et al. Use of snus and acute myocardial infarction: pooled analysis of eight prospective observational studies. Eur J Epidemiol 2012; 27: 771–9.
7. Luo J, Ye W, Zendehdel K et al. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet 2007; 369: 2015–20.
8. Nordenvall C, Nilsson PJ, Ye W, Nyrén O. Smoking, snus use and risk of right- and left-sided colon, rectal and anal cancer: a 37-year follow-up study. Int J Cancer 2011; 128: 157–65.
9. Nordenvall C, Nilsson PJ, Ye W, Andersson TM, Nyrén O. Tobacco use and cancer survival: a cohort study of 40,230 Swedish male construction workers with incident cancer. Int J Cancer 2013; 132: 155–61.
10. Pan A, Wang Y, Talaei M, Hu FB, Wu T. Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2015; 3: 958–67.
11. Bajaj M. Nicotine and insulin resistance: when the smoke clears. Diabetes 2012; 61: 3078–80.
12. Bergman BC, Perreault L, Hunerdosse D et al. Novel and reversible mechanisms of smoking-induced insulin resistance in humans. Diabetes 2012; 61: 3156–66.
13. Liu S, Tinker L, Song Y et al. A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. Arch Intern Med 2007; 167: 1676–85.
14. Ostgren CJ, Lindblad U, Ranstam J, Melander A, Melander L. Skaraborg Hypertension and Diabetes Project. Associations between smoking and beta-cell function in a non-hypertensive and non-diabetic population. Skaraborg Hypertension and Diabetes Project. Diabet Med 2000; 17: 445–50.
15. Digard H, Sholar MB, Goletiani N, Siegel AJ, Mello NK. Determination of nicotine absorption from multiple tobacco products and nicotine gum. Nicotine Tob Res 2013; 15: 255–61.
16. Persson PG, Carlsson S, Svanström L, Ostenson CG, Efendic S, Grill V. Cigarette smoking, oral moist snuff use and glucose intolerance. J Intern Med 2000; 248: 103–10.
17. Östenson CG, Hilding A, Grill V, Efendic S. High consumption of smokeless tobacco (“snus”) predicts increased risk of type 2 diabetes in a 10-year prospective study of middle-aged Swedish men. Scand J Public Health 2012; 40: 730–7.
18. Eliasson M, Asplund K, Nasic S, Rodu B. Influence of smoking and snus on the prevalence and incidence of type 2 diabetes amongst men: the northern Sweden MONICA study. J Intern Med 2004; 256: 101–10.
19. Rasouli B, Andersson T, Carlsson PO et al. Use of Swedish smokeless tobacco (snus) and the risk of Type 2 diabetes and latent autoimmune diabetes of adulthood (LADA). Diabet Med 2016 Jun 29; doi:10.1111/dme.13179.
20. Pedersen W, von Soest T. Tobacco use among Norwegian adolescents: from cigarettes to snus. Addiction 2014; 109: 1154–62.
21. Norberg M, Malmberg G, Ng N, Broström G. Who is using snus? - Time trends, socioeconomic and geographic characteristics of snus users in the ageing Swedish population. BMC Public Health 2011; 11: 929.
22. Agaku IT, Awopegba AJ, Filippidis FT. The impact of inter-survey differences in the definition of current smokeless tobacco use on comparability of US national and state-specific prevalence estimates, 2009-2011. Prev Med 2015; 74: 86–92.
23. Centers for Disease Control and Prevention. State-Specific Prevalence of Current Cigarette Smoking and Smokeless Tobacco Use Among Adults Aged ≥18 Years — United States, 2011–2013. Morb Mortal Wkly Rep 2015; 64: 532–6.
24. Zhu SH, Gamst A, Lee M, Cummins S, Yin L, Zoref L. The use and perception of electronic cigarettes and snus among the U.S. population. PLoS One 2013; 8: e79332.
25. Norberg M, Wall S, Boman K, Weinehall L. The Västerbotten Intervention Programme: background, design and implications. Glob Health Action 2010; 22: 3.
26. Svensson AC, Fredlund P, Laflamme L et al. Cohort profile: the Stockholm Public Health Cohort. Int J Epidemiol 2013; 42: 1263–72.
27. Manjer J, Carlsson S, Elmståhl S et al. The Malmö Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 2001; 10: 489–99.
28. Lagerros YT, Bellocco R, Adami HO, Nyrén O. Measures of physical activity and their correlates: the Swedish National March Cohort. Eur J Epidemiol 2009; 24: 161–9.
29. Lichtenstein P, Sullivan PF, Cnattingius S et al. The Swedish Twin Registry in the third millennium: an update. Twin Res Hum Genet 2006; 9: 875–82.
30. Ludvigsson JF, Andersson E, Ekbom A et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011; 11: 450.
31. Wettermark B, Hammar N, Fored CM et al. The new Swedish Prescribed Drug Register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726–35.
32. Enhörning S, Wang TJ, Nilsson PM et al. Plasma copeptin and the risk of diabetes mellitus. Circulation 2010; 121: 2102–8.
33. Allison PD. Survival Analysis Using SAS: A Practical Guide. SAS Institute Inc., Cary, NC, USA: Sas Inst, 2010.
34. Allison PD. Event History Analysis: Regression for Longitudinal Event Data. Newbury Park, CA: Sage, 1984.
35. Hartung J, Knapp G, Sinha BK. Statistical Meta-Analysis with Applications. Hoboken, NJ: Wiley, 2008. ISBN 978-0-470-29089-7.
36. Mendelson JH, Sholar MB, Goletiani N, Siegel AJ, Mello NK. Effects of low- and high-nicotine cigarette smoking on mood states and the HPA axis in men. Neuropsychopharmacology 2005; 30: 1751–63.
37. Holm H, Jarvis MJ, Russell MA, Feyerabend C. Nicotine intake and dependence in Swedish snuff takers. Psychopharmacology 1992; 108: 507–11.
38. Andersson G, Björnberg G, Curvall M. Oral mucosal changes and nicotine disposition in users of Swedish smokeless tobacco products: a comparative study. J Oral Pathol Med 1994; 23: 161–7.
39. Andersson T, Ahlbom A, Carlsson S. Diabetes Prevalence in Sweden at Present and Projections for Year 2050. PLoS One 2015; 10: e0143084.
40. Eliasson M, Asplund K, Evrin PE, Lundblad D. Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin. The Northern Sweden MONICA Study. Atherosclerosis 1995; 113: 41–53.
41. Hergens MP, Galanti R, Hansson J et al. Use of Scandinavian moist smokeless tobacco (snus) and the risk of atrial fibrillation. Epidemiology 2014; 25: 872–6.
42. International Diabetes Federation IDF diabetes Atlas 7th edition 2015. http://www.diabetesatlas.org/.